Brief: Cardiff Oncology Announces New Data From Lead Clinical Program In Kras-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate And Progression Free Survival

Cardiff Oncology

18/01/2022 22:29

Jan 18 (Reuters) - Cardiff Oncology Inc  CRDF.O :
    * CARDIFF ONCOLOGY ANNOUNCES NEW DATA FROM LEAD CLINICAL
PROGRAM
IN KRAS-MUTATED METASTATIC COLORECTAL CANCER SHOWING ROBUST
OBJECTIVE RESPONSE RATE AND PROGRESSION FREE SURVIVAL
    * CARDIFF ONCOLOGY -  34% PATIENTS TREATED PER PROTOCOL AT
RP2D IN
COMBINATION WITH FOLFIRI, BEVACIZUMAB ACHIEVED COMPLETE RESPONSE
OR PARTIAL RESPONSE
    * CARDIFF ONCOLOGY INC - 5 OF 48 (10%) PATIENTS DISCONTINUED
TRIAL
TO PURSUE POTENTIALLY CURATIVE METASTASIS-DIRECTED THERAPY
    * CARDIFF -COMBINATION REGIMEN OF ONVANSERTIB PLUS
FOLFIRI/BEVACIZUMAB IS WELL TOLERATED WITH NO MAJOR OR
UNEXPECTED TOXICITIES ATTRIBUTED TO ONVANSERTIB
    * CARDIFF ONCOLOGY - MEDIAN PROGRESSION-FREE SURVIVAL ACROSS
ALL
RESPONSE-EVALUABLE PATIENTS NOT YET BEEN REACHED IN THOSE
TREATED PER PROTOCOL AT RP2D
    * CARDIFF ONCOLOGY INC - 35% OF  PATIENTS ACROSS ALL DOSE
LEVELS
ACHIEVED A CR OR PR IN CLINICAL PROGRAM IN KRAS-MUTATED
METASTATIC COLORECTAL CANCER

Source text for Eikon:  ID:nPn2F0mHca 
Further company coverage:  CRDF.O 

 ((Reuters.Briefs@thomsonreuters.com;))